Enhancer of Zeste Homolog 2 Protein

A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation of circadian protein gene PROMOTER REGIONS, and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS.

Also Known As:

Networked: 636 relevant articles (3 outcomes, 72 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Liu, Na: 8 articles (10/2022 - 01/2016)
2.	Zhuang, Shougang: 7 articles (10/2022 - 01/2016)
3.	Cao, Wei: 6 articles (06/2020 - 11/2011)
4.	Tang, Lunxian: 5 articles (10/2022 - 11/2019)
5.	Zhang, Ying: 5 articles (08/2021 - 07/2007)
6.	Hamamoto, Ryuji: 5 articles (05/2019 - 07/2011)
7.	Chinnaiyan, Arul M: 5 articles (01/2019 - 10/2002)
8.	Toyokawa, Gouji: 5 articles (01/2019 - 07/2011)
9.	Cai, Jing: 5 articles (06/2018 - 04/2013)
10.	Wang, Zehua: 5 articles (06/2018 - 04/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2023 - "SHR2554, a novel oral Enhancer of Zeste Homolog 2 inhibitor, shows broad-spectrum anti-tumor efficacy in preclinical studies. " 06/01/2021 - "This study was designed to compare epigenetic alterations observed in Enhancer of Zeste Homolog 2 (EZH2)-target genes between plasma-derived exosomes and primary tumors in DLBCL patients. " 12/02/2020 - "Moreover, more in-depth mechanism studies showed that carcinogenicity of HOXA-AS2 exerted mainly through binding with the epigenetic inhibitor Enhancer of zeste homolog 2 (EZH2) and then inhibiting the expression of Large Tumor Suppressor 2 (LATS2). " 12/20/2016 - "Numerous studies have highlighted the role of the PRC2 catalytic component enhancer of zeste homolog 2 (EZH2) in neoplastic development and progression, and EZH2 mutations have been identified in various malignancies. " 01/01/2015 - "This study aimed to explore the associations between enhancer of zeste homolog 2 (EZH2) and patient survival in various cancers. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "The aim of the present study was to investigate the correlation of enhancer of Zeste homolog 2 (EZH2) and SET and MYND domain containing 3 (SMYD3) gene polymorphisms with breast cancer susceptibility and prognosis. " 01/01/2017 - "Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions." 10/01/2019 - "Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in breast cancer and plays an important role in maintaining the cell proliferative capacity. " 01/01/2017 - "However, the change in expression levels of enhancer of zeste homolog 2 (EZH2) between primary and metastatic lesions has not been determined in metastatic breast cancer. " 10/01/2012 - "In addition, enhancer of zeste homolog 2 gene silencing resulted in a significant reduction in tumor growth (P < .01) in the orthotopic MB-231 mouse model of breast carcinoma. "
3.	Neoplasm Metastasis (Metastasis) 07/01/2013 - "Enhancer of zeste homolog 2 expression in human tissue samples was significantly associated with increased stage, grade, depth of invasion, and nodal metastasis. " 01/01/2020 - "The aim of this study was to investigate whether microRNA-625-3p participated in the malignant progression of gastric cancer and inhibited GCa metastasis by regulating EZH2 (Enhancer of zeste homolog 2). " 11/01/2019 - "This study was designed to investigate whether microRNA-130-5p could promote the progression and metastasis of lung cancer by targeting enhancer of zeste homolog 2 (EZH2). " 10/01/2022 - "The expression of enhancer of zeste homolog 2 (EZH2) is correlated with breast cancer metastasis, but its function in bone metastasis hasn't been well-explored. " 01/01/2020 - "Enhancer of Zeste Homolog 2 (EZH2), a key epigenetic regulator, is involved in breast cancer progression and metastasis. "
4.	Carcinogenesis 10/01/2020 - "Previous studies have reported that enhancer of zeste homolog 2 (EZH2) and long non-coding RNAs (lncRNAs) have abnormal expression levels in NB and participate in tumorigenesis and NB development. " 11/01/2021 - "Enhancer of zeste homolog 2 (EZH2) has been extensively investigated to participate in diverse biological processes, including carcinogenesis, the cell cycle, X-chromosome inactivation, and early embryonic development. " 12/01/2013 - "Enhancer of zeste homolog 2 (EZH2) promotes carcinogenesis by epigenetically silencing tumor suppressor genes. " 11/01/2011 - "To assess OSCC risk of OLs, we investigated the role of the transcriptional repressor enhancer of zeste homolog 2 (EZH2) in oral tumorigenesis and its clinical implication as an OSCC risk predictor. " 01/01/2021 - "Enhancer of zeste homolog 2 (EZH2) is aberrantly expressed or mutated in multiple types of cancer cells and plays an oncogenic role in tumorigenesis and development in most cancers. "
5.	Lung Neoplasms (Lung Cancer) 08/25/2023 - "This study aimed to explore the interaction between the tumor-associated macrophage (TAM) and enhancer of zeste homolog 2 (EZH2) in tumor microenvironment of lung cancer are obscure. " 03/01/2023 - "Enhancer of zeste homolog 2 (EZH2) is an important epigenetic regulator, and is associated with the malignant progression of lung cancer. " 01/01/2021 - "Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells." 05/20/2019 - "With the development of epigenetics, the researchers found that enhancer of Zeste homolog 2 (EZH2) is highly expressed in lung cancer tissue and its expression is closely related to the prognosis. " 01/01/2019 - "Enhancer of zeste homolog 2 (EZH2) is reported to be involved in lung cancer pathogenesis via the epigenetic regulation of various genes. "

Related Drugs and Biologics

1.	Chromatin
2.	Proteins (Proteins, Gene)
3.	Long Noncoding RNA
4.	Histone Methyltransferases
5.	Lysine (L-Lysine)
6.	Polycomb-Group Proteins
7.	MicroRNAs (MicroRNA)
8.	Biomarkers (Surrogate Marker)
9.	GSK-2816126
10.	Histone Demethylases

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Neoadjuvant Therapy
4.	Immunotherapy
5.	Castration